View Financial HealthNovozymes 배당 및 자사주 매입배당 기준 점검 4/6Novozymes 수익으로 충분히 충당되는 현재 수익률 1.68% 보유한 배당금 지급 회사입니다.핵심 정보1.7%배당 수익률0.1%자사주 매입 수익률총 주주 수익률1.8%미래 배당 수익률2.1%배당 성장률6.4%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향68%최근 배당 및 자사주 매입 업데이트공시 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.모든 업데이트 보기Recent updatesReported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.공시 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark공시 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.Buy Or Sell Opportunity • Jan 22Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €55.22. The fair value is estimated to be €45.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.3% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.공시 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).Board Change • Sep 11High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: NZM2 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: NZM2 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Novozymes 배당 수익률 vs 시장NZM2의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NZM2)1.7%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Chemicals)3.7%분석가 예측 (NZM2) (최대 3년)2.1%주목할만한 배당금: NZM2 의 배당금( 1.68% )은 German 시장에서 배당금 지급자의 하위 25%( 1.54% )보다 높습니다.고배당: NZM2 의 배당금( 1.68% )은 German 시장에서 배당금 지급자의 상위 25%( 4.55% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 68.1% )을 통해 NZM2 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 52.4% )로 NZM2 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 13:01종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Novozymes A/S는 28명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Alexander SloaneBarclaysCezara LozneanuBarclaysSebastian SatzBarclays25명의 분석가 더 보기
공시 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).
Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
Reported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.
공시 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).
Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark
공시 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
Buy Or Sell Opportunity • Jan 22Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €55.22. The fair value is estimated to be €45.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.3% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.
공시 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
Board Change • Sep 11High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.